ADMA Biologics Inc (NASDAQ:ADMA) Shares Bought by Principal Financial Group Inc.

Principal Financial Group Inc. boosted its stake in shares of ADMA Biologics Inc (NASDAQ:ADMA - Free Report) by 2.3% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,288,121 shares of the biotechnology company's stock after buying an additional 29,107 shares during the quarter. Principal Financial Group Inc. owned 0.54% of ADMA Biologics worth $25,556,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently modified their holdings of the company. Raymond James Financial Inc. purchased a new stake in shares of ADMA Biologics in the fourth quarter valued at about $19,076,000. JPMorgan Chase & Co. lifted its holdings in shares of ADMA Biologics by 272.5% in the fourth quarter. JPMorgan Chase & Co. now owns 767,265 shares of the biotechnology company's stock valued at $13,159,000 after purchasing an additional 561,310 shares in the last quarter. Victory Capital Management Inc. lifted its holdings in shares of ADMA Biologics by 52.8% in the fourth quarter. Victory Capital Management Inc. now owns 109,948 shares of the biotechnology company's stock valued at $1,886,000 after purchasing an additional 38,002 shares in the last quarter. Sei Investments Co. lifted its holdings in shares of ADMA Biologics by 147.2% in the fourth quarter. Sei Investments Co. now owns 527,272 shares of the biotechnology company's stock valued at $9,043,000 after purchasing an additional 314,013 shares in the last quarter. Finally, New York State Teachers Retirement System lifted its holdings in shares of ADMA Biologics by 96.2% in the first quarter. New York State Teachers Retirement System now owns 221,890 shares of the biotechnology company's stock valued at $4,402,000 after purchasing an additional 108,800 shares in the last quarter. Hedge funds and other institutional investors own 75.68% of the company's stock.

Insider Buying and Selling

In related news, Director Steve Elms sold 194,749 shares of the company's stock in a transaction that occurred on Monday, June 16th. The shares were sold at an average price of $20.24, for a total transaction of $3,941,719.76. Following the completion of the transaction, the director owned 87,330 shares of the company's stock, valued at approximately $1,767,559.20. This represents a 69.04% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Lawrence P. Guiheen sold 20,000 shares of the company's stock in a transaction that occurred on Monday, June 9th. The stock was sold at an average price of $20.96, for a total transaction of $419,200.00. Following the transaction, the director directly owned 94,830 shares of the company's stock, valued at $1,987,636.80. This trade represents a 17.42% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 464,621 shares of company stock valued at $9,644,269. Insiders own 3.70% of the company's stock.

Analyst Upgrades and Downgrades

Several analysts have issued reports on ADMA shares. Wall Street Zen downgraded shares of ADMA Biologics from a "hold" rating to a "sell" rating in a report on Friday, May 9th. Raymond James Financial upped their price objective on shares of ADMA Biologics from $25.00 to $32.00 and gave the company a "strong-buy" rating in a research note on Thursday, May 8th.

ADMA Biologics Stock Performance

Shares of ADMA opened at $17.81 on Wednesday. The company has a debt-to-equity ratio of 0.22, a quick ratio of 3.36 and a current ratio of 6.58. The company has a market capitalization of $4.25 billion, a price-to-earnings ratio of 20.95 and a beta of 0.43. The company's 50 day simple moving average is $19.99 and its 200 day simple moving average is $18.73. ADMA Biologics Inc has a 1 year low of $10.21 and a 1 year high of $25.67.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The biotechnology company reported $0.14 EPS for the quarter, missing the consensus estimate of $0.16 by ($0.02). ADMA Biologics had a return on equity of 47.16% and a net margin of 45.01%. The company had revenue of $114.80 million for the quarter, compared to analyst estimates of $116.40 million. During the same period last year, the company posted $0.08 EPS. The business's revenue for the quarter was up 40.2% on a year-over-year basis. On average, sell-side analysts predict that ADMA Biologics Inc will post 0.51 EPS for the current year.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.

Want to see what other hedge funds are holding ADMA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ADMA Biologics Inc (NASDAQ:ADMA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.